List of Excipients in Branded Drug PHENYLEPHRINE HYDROCHLORIDE INJECTION, SOLUTION

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Dr Reddy's Laboratories Inc	PHENYLEPHRINE HYDROCHLORIDE INJECTION, SOLUTION	phenylephrine hydrochloride injection, solution	43598-182	HYDROCHLORIC ACID
Dr Reddy's Laboratories Inc	PHENYLEPHRINE HYDROCHLORIDE INJECTION, SOLUTION	phenylephrine hydrochloride injection, solution	43598-182	NITROGEN
Dr Reddy's Laboratories Inc	PHENYLEPHRINE HYDROCHLORIDE INJECTION, SOLUTION	phenylephrine hydrochloride injection, solution	43598-182	SODIUM CHLORIDE
Dr Reddy's Laboratories Inc	PHENYLEPHRINE HYDROCHLORIDE INJECTION, SOLUTION	phenylephrine hydrochloride injection, solution	43598-182	WATER

Phenylephrine Hydrochloride Injection Excipient Strategy and Commercial Opportunities

Last updated: August 28, 2026

Phenylephrine hydrochloride injection is a mature, multisource injectable market in which excipient differentiation is limited but commercially meaningful. The strongest opportunities are ready-to-use low-concentration presentations, preservative-free single-dose packaging, improved dilution stability, reduced medication-error risk, and supply-chain reliability. The active ingredient has limited conventional patent protection; competitive barriers are more likely to arise from sterile manufacturing, container-closure systems, labeling, procurement contracts, and demonstrated product quality.

What is the FDA regulatory status of phenylephrine hydrochloride injection?

Phenylephrine hydrochloride injection is an FDA-approved prescription vasopressor used to treat clinically significant hypotension resulting primarily from vasodilation, including perioperative hypotension associated with anesthesia. FDA-approved presentations include concentrated injectable products that require dilution and ready-to-use lower-concentration products intended for direct administration or infusion, depending on the product labeling.[1]

The market includes:

Product characteristic	Commercial relevance
Active ingredient	Phenylephrine hydrochloride
Therapeutic class	Alpha-1 adrenergic receptor agonist; vasopressor
Primary setting	Operating rooms, intensive care units, emergency departments
Common concentration formats	10 mg/mL concentrate; lower-concentration ready-to-use solutions
Dosage forms	Single-dose vials, ampules, prefilled syringes, infusion containers
Regulatory pathway	NDA, ANDA, or 505(b)(2), depending on product and reference
Administration	Intravenous bolus or infusion; some products also have other labeled routes
Key quality attributes	Sterility, potency, pH, particulate control, endotoxin, extractables, stability

The concentrated 10 mg/mL format creates a dilution step before administration. Lower-concentration presentations reduce preparation requirements and may lower the risk of calculation, dilution, and syringe-labeling errors. Product-specific labeling controls the permitted administration route, dose, dilution, and storage conditions.[1]

What excipients are used in phenylephrine hydrochloride injection?

The principal excipient strategy is aqueous pH and tonicity control. Excipients vary by manufacturer, strength, container, and regulatory pathway. Product labels and approved drug databases should be used to confirm the exact composition for each commercial product.[1,2]

Common excipient functions include:

Excipient function	Candidate materials	Strategic purpose
Vehicle	Sterile Water for Injection	Dissolves phenylephrine hydrochloride and supports parenteral administration
Tonicity adjustment	Sodium chloride	Reduces risk of injection-site discomfort and supports physiologic compatibility
Buffering	Sodium citrate and citric acid, or another validated buffer system	Controls pH during manufacture and storage
pH adjustment	Hydrochloric acid or sodium hydroxide	Brings the formulation within the approved pH range
Antimicrobial preservation	Product-specific preservative, where applicable	May support multidose packaging but can restrict patient populations and administration settings
Container compatibility	No functional excipient in the formulation itself	Requires selection of glass, polymer, elastomer, and syringe materials that minimize adsorption and extractables

Phenylephrine hydrochloride is highly water soluble, so solubility is generally less commercially important than pH stability, oxidation control, particulate performance, and container compatibility. A simple aqueous formulation can therefore be competitive if it delivers an extended shelf life, consistent potency, and a convenient presentation.

How should pH and tonicity be managed?

The formulation should use the lowest excipient burden that maintains chemical and physical stability. Excessive buffering can increase compatibility risks, alter injection tolerability, or complicate comparability against the reference product. Tonicity adjustment should be evaluated across the final marketed concentration rather than only in the concentrated stock solution.

The development program should assess:

• pH drift through the proposed shelf life
• phenylephrine assay and related substances
• color formation
• visible and subvisible particles
• container-closure integrity
• compatibility with common infusion solutions
• adsorption to syringes and tubing
• compatibility with elastomeric stoppers
• photostability
• oxygen sensitivity and headspace effects

USP general chapters addressing sterile products, particulate matter, bacterial endotoxins, container integrity, and extractables and leachables provide the relevant quality framework.[3]

What formulations are protected by phenylephrine injection patents?

Phenylephrine hydrochloride injection is primarily a mature generic product category. The basic aqueous injectable formulation is unlikely to support broad composition-of-matter exclusivity because the active ingredient and simple parenteral formulation have been used for decades.

Potentially protectable subject matter includes:

1. A defined concentration and pH range combined with stability performance.
2. A ready-to-use prefilled syringe or cartridge.
3. A specific low-concentration formulation with a validated shelf life.
4. A container-closure system that limits adsorption, oxidation, or particulate generation.
5. A proprietary premixed infusion bag.
6. Manufacturing controls that improve sterility assurance or reduce degradation.
7. A formulation compatible with automated anesthesia or infusion systems.
8. A method of reducing preparation errors through a particular labeled presentation.

A formulation patent must provide more than routine selection of water, sodium chloride, citrate, and pH adjusters. Commercially meaningful claims would need defensible data showing unexpected stability, reduced impurities, improved compatibility, or a measurable administration advantage.

When does phenylephrine injection lose exclusivity?

There is no single market-wide loss-of-exclusivity date for phenylephrine hydrochloride injection. Multiple manufacturers can hold separate FDA approvals, and product-level exclusivity depends on the relevant NDA or ANDA.

For mature injectable products, the practical position is:

Exclusivity category	Relevance to phenylephrine injection
New chemical entity exclusivity	Not relevant to this established active ingredient
Orphan exclusivity	Not generally applicable to the routine injectable product
New clinical investigation exclusivity	Possible only for a qualifying new indication or change
Pediatric exclusivity	Product-specific and temporary
Listed-patent exclusivity	Depends on patents listed against a specific NDA
Generic competition	Already established across several presentations

The Orange Book records patents and exclusivity by approved application, not by active ingredient alone.[4] A sponsor evaluating entry must therefore review the reference product, listed patents, expiration dates, and any regulatory exclusivity associated with the intended dosage form.

What is the Orange Book status of phenylephrine hydrochloride injection?

The Orange Book should be reviewed by application number and dosage form. A generic sponsor should not assume that the existence of an approved phenylephrine injection automatically establishes a common patent barrier across all strengths and presentations.

For an ANDA strategy, the key questions are:

• Is there a current reference listed drug for the proposed strength and dosage form?
• Are relevant patents listed against that reference?
• Does the proposed product have the same route, strength, dosage form, and conditions of use?
• Can inactive-ingredient differences be justified?
• Does the applicant need a Paragraph IV certification?
• Are labeling differences required because of excipient composition or presentation?

If no relevant patent is listed against the selected reference product, a Paragraph IV certification may not be necessary. If a listed patent covers the formulation, container, method of use, or other approved feature, the applicant may need to certify under Paragraph I, II, III, or IV, depending on the patent status and proposed launch timing.[5]

Which companies are challenging phenylephrine injection patents?

The commercial market is better characterized by multisource generic competition than by a single high-profile patent dispute. Manufacturers and suppliers have included major generic injectable companies, hospital-focused manufacturers, contract manufacturers, and specialty pharmaceutical firms. Product availability changes by strength, container, NDC, and supply status.

A sponsor should distinguish between:

• A company challenging an Orange Book patent through Paragraph IV.
• A company launching an ANDA after patent expiry.
• A company introducing a different presentation through an NDA or 505(b)(2).
• A contract manufacturer supplying an approved product for another labeler.
• A wholesaler or repackager distributing an existing product.

Public litigation databases and FDA approval records should be searched by the relevant NDA, ANDA, manufacturer, and patent number. Searching only "phenylephrine" can produce unrelated nasal, ophthalmic, and combination products.

What excipient strategy creates the strongest commercial opportunity?

Ready-to-use low-concentration injection

The clearest opportunity is a ready-to-use product that avoids bedside dilution. A low-concentration prefilled syringe can compete on preparation time, dosing consistency, and medication-safety workflow. The formulation should be preservative-free for single-dose use and packaged in a syringe compatible with hospital administration systems.

The value proposition is strongest in operating rooms and emergency settings, where rapid vasopressor administration is common and pharmacy preparation capacity is limited.

Stable premixed infusion products

A premixed infusion bag or smaller infusion container could target intensive care and perioperative use. The development burden is higher because the product must demonstrate stability in the final container, during transport, and after connection to administration equipment.

Potential differentiators include:

• Multiple standardized concentrations
• Longer in-use stability
• Clear labeling and color differentiation
• Compatibility with common infusion pumps
• Reduced pharmacy compounding
• Improved stock management across hospital departments

Preservative-free single-dose formats

Preservative-free vials, ampules, and prefilled syringes are suitable for single-patient administration. A preservative-free strategy avoids concerns associated with antimicrobial agents in vulnerable patient populations and simplifies hospital formulary review.

The tradeoff is that single-dose packaging can increase manufacturing and packaging costs. The product must justify the cost through workflow savings, safety advantages, or supply reliability.

Concentrate with improved dilution instructions

A lower-cost opportunity is an improved concentrated product with clear dilution instructions, standardized dose tables, and compatible diluents. The formulation itself may not be highly differentiated, but the presentation can reduce preparation variability.

This approach has lower development risk than a new ready-to-use product but faces stronger price competition.

How strong is the patent estate for phenylephrine hydrochloride injection?

The patent estate is generally weak for the core active ingredient and basic aqueous formulation. The stronger barriers are operational and regulatory:

Barrier	Relative strength
Active-ingredient patent	Low
Basic aqueous formulation patent	Low to moderate
Narrow stability formulation patent	Moderate if supported by unexpected data
Prefilled syringe system	Moderate
Proprietary container and closure	Moderate
Sterile manufacturing capability	High for new entrants
FDA inspection and quality systems	High
Hospital purchasing contracts	Moderate to high
Shortage-resilient supply chain	High commercial value

A narrow patent can still matter if it covers the only commercially practical ready-to-use presentation. Its value depends on claim scope, enablement, enforceability, expiration date, and whether competing manufacturers can design around the formulation or container.

What manufacturing and IP barriers affect generic launch?

Sterile injectable manufacturing is the principal technical barrier. A sponsor needs validated aseptic processing or terminal sterilization, depending on the formulation and container system. The product must meet requirements for sterility, endotoxins, particulate matter, extractables and leachables, and container-closure integrity.[3]

The most relevant manufacturing risks are:

• Subvisible particulate formation
• Stopper or syringe-component interaction
• Potency loss during storage
• Oxygen-related degradation
• Batch-to-batch pH variation
• Filling accuracy at low concentrations
• Sterility assurance for small-volume parenterals
• Stability after dilution or withdrawal
• Supply interruptions for glass, elastomers, or polymer syringes

A formulation that uses conventional excipients may still create defensible know-how through process controls, filling parameters, headspace management, and packaging selection. Trade-secret protection may be more durable than a narrow formulation patent where the process is difficult to reverse engineer.

What generic launch risks exist for phenylephrine injection?

Generic launch risk is concentrated in regulatory equivalence, supply reliability, and market access.

Regulatory risk

A concentrated product and a ready-to-use product may not be interchangeable from an ANDA perspective if their strength, dosage form, administration instructions, or inactive ingredients differ materially. A sponsor may need a 505(b)(2) application rather than an ANDA where the proposed product relies on a distinct formulation or presentation.[5]

Commercial risk

Hospital buyers often select injectable products through group purchasing organizations, national contracts, and shortage-driven substitutions. A technically differentiated product can fail commercially if it lacks reliable supply, competitive pricing, or pharmacy workflow support.

Launch scenarios

Scenario	Commercial result
Low-cost concentrated vial	High price pressure; broad institutional use
Ready-to-use prefilled syringe	Higher value per unit; stronger differentiation
Premixed infusion bag	Larger pharmacy and ICU opportunity; greater stability burden
Specialty low-volume presentation	Potentially attractive margin; narrower demand
Shortage-driven launch	Rapid uptake but uncertain persistence
Dual-source hospital contract	More durable volume and lower customer-acquisition cost

How does phenylephrine injection compare with competing vasopressors?

Phenylephrine competes with norepinephrine, epinephrine, vasopressin, and other vasopressor products. Product selection depends on clinical indication, hemodynamic profile, institutional protocol, and presentation.

Product	Primary commercial differentiator
Phenylephrine injection	Alpha-1 vasoconstriction; common perioperative use
Norepinephrine injection	Broad ICU and shock use; frequent premixed formats
Epinephrine injection	Resuscitation and critical care applications
Vasopressin injection	Non-catecholamine vasoconstrictor; distinct clinical positioning

Phenylephrine’s strongest commercial niche is workflow-sensitive perioperative use, particularly where rapid, standardized bolus dosing is required. The product competes less on novel pharmacology than on concentration, packaging, availability, and ease of administration.

What licensing deals and settlement agreements affect the market?

The core phenylephrine hydrochloride injection market is not generally defined by a major branded licensing structure. Relevant commercial arrangements are more likely to involve contract manufacturing, technology transfer, authorized generic supply, hospital purchasing agreements, and private-label distribution.

Settlement agreements matter only where an ANDA applicant challenges a listed patent. Their business effect may include a delayed launch date, an authorized-generic arrangement, supply rights, or restrictions on the approved presentation. These agreements should be assessed by docket, patent number, application number, and settlement terms rather than by active ingredient alone.

Key Takeaways

• Phenylephrine hydrochloride injection is a mature multisource injectable market.
• The basic aqueous formulation has limited patent strength.
• Ready-to-use prefilled syringes and premixed infusion products offer the strongest commercial differentiation.
• Preservative-free single-dose packaging is generally preferable for hospital use.
• pH control, stability, particulate performance, and container compatibility are the main formulation priorities.
• Sterile manufacturing, quality systems, and supply reliability are stronger barriers than active-ingredient patents.
• Orange Book and Paragraph IV analysis must be performed by reference product, application number, strength, and dosage form.
• Hospital contracts, shortage performance, and medication-error reduction can have greater commercial value than a narrow formulation patent.

FAQs

Can sodium chloride be removed from phenylephrine hydrochloride injection?

It can be considered if the final formulation meets tonicity, tolerability, stability, and labeling requirements. Removing sodium chloride may create a regulatory difference from the reference product and requires product-specific justification.

Is a preservative required in phenylephrine hydrochloride injection?

No universal preservative requirement applies to all presentations. Single-dose products are commonly developed without antimicrobial preservatives, while multidose products require a separate preservative and multidose-container justification.

Can phenylephrine injection be sold in a prefilled syringe under an ANDA?

Potentially, but the proposed syringe must satisfy the applicable sameness and inactive-ingredient requirements for the ANDA pathway. A materially different presentation may require a 505(b)(2) application.

What excipient has the greatest impact on product stability?

The buffer and pH-control system usually has the greatest direct impact, although the container, stopper, syringe, oxygen exposure, light, and storage temperature can be equally important to shelf-life performance.

Is phenylephrine hydrochloride injection a strong candidate for 505(b)(2) development?

It can be, particularly for a new ready-to-use concentration, premixed infusion, or delivery system that differs materially from an approved reference product and offers a clinically or operationally relevant advantage.

References

1. U.S. Food and Drug Administration. (n.d.). Phenylephrine hydrochloride injection prescribing information. DailyMed.
2. National Library of Medicine. (n.d.). DailyMed: Phenylephrine hydrochloride injection product labeling.
3. United States Pharmacopeia. (2024). United States Pharmacopeia and National Formulary. U.S. Pharmacopeial Convention.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
5. U.S. Food and Drug Administration. (2024). Abbreviated new drug application submissions: Policy and regulatory requirements.